Ondine Biomedical (OBI) H2 2023 earnings summary

Executive summary

• Achieved strong commercial growth in 2023 with nearly doubled revenue, exponential hospital adoption, and 100% hospital retention, expanding sites nearly fourfold since early 2023.

• Over 150,000 patients treated with no serious adverse events and real-world evidence showing over 50% infection reduction and healthcare cost savings.

• Strategic partnership with HCA Healthcare for U.S. Phase 3 clinical studies, targeting Q3 2024 start and commercialization in 2026.

• Scalable business model with sharply reduced sales cycle and recurring revenue from consumables and flexible light source options.

• Steriwave platform demonstrated significant reductions in surgical site infections in real-world settings.

Financial highlights

• 2023 revenues nearly doubled to $1.2 million from $0.6 million in 2022, driven by new hospital implementations and higher average sale prices.

• Gross margin improved to 58% in 2023 from 45% in 2022, aided by cost reductions and higher pricing.

• Total operating expenses decreased to $15.5 million from $19.2 million, with net loss narrowing to $14.4 million and loss per share improving to $(0.07).

• Share-based costs decreased by almost $1 million; disciplined discretionary spending extended cash runway.

• Sales and marketing costs rose by only 30% despite revenue doubling, reflecting operational efficiencies.

Outlook and guidance

• Phase III U.S. clinical study to begin in Q3 2024, targeting completion and FDA submission in 2025, with U.S. commercialization expected in 2026.

• Ready for rapid scaling with current site and vendor capacity supporting up to 11 million annual production units, expandable with minimal investment.

• Focus on ex-U.S. growth, especially in Canada and the EU, while awaiting U.S. regulatory approval.

• Cash flow neutrality projected with a doubling of business; profitability could be accelerated with third-party partnerships.